GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study
The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Abstract
The role of glucose-stimulated release of GLP-1 in the development of obesity and type 2 diabetes is unclear. We assessed GLP-1 response to oral glucose in a large study population of lean and obese men and women with normal and impaired glucose regulation. Circulating concentrations of glucose, insulin, and GLP-1 during an oral glucose tolerance test (OGTT) were analyzed in individuals with normal glucose tolerance (NGT) (n = 774), prediabetes (n = 525), or screen-detected type 2 diabetes (n = 163) who attended the Danish ADDITION-PRO study (n = 1,462). Compared with individuals with NGT, women with prediabetes or type 2 diabetes had 25% lower GLP-1 response to an OGTT, and both men and women with prediabetes or type 2 diabetes had 16-21% lower 120-min GLP-1 concentrations independent of age and obesity. Obese and overweight individuals had up to 20% reduced GLP-1 response to oral glucose compared with normal weight individuals independent of glucose tolerance status. Higher GLP-1 responses were associated with better insulin sensitivity and β-cell function, older age, and lesser degree of obesity. Our findings indicate that a reduction in GLP-1 response to oral glucose occurs prior to the development of type 2 diabetes and obesity, which can have consequences for early prevention strategies for diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is a limited body of evidence supporting a modest reduction in gut GLP-1 release in people living with obesity, which may be partly heritable (14, 132‐134).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [133]
In the citing paper
“There is a limited body of evidence supporting a modest reduction in gut GLP-1 release in people living with obesity, which may be partly heritable (14, 132‐134).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [133]
In the citing paper
“From a diabetes prevention perspective, the GLP-1-releasing effects of PUFAs could be particularly important, given that obese patients have lower GLP-1 responses to oral glucose than individuals of normal weight, irrespective of the glycemic status [52,53].”
From Mediterranean diet nutrients to turn the tide against insulin resistance and related diseases (2020) · cites this paper as [52]
Citations
Cites
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“In type 2 diabetes, the incretin effect is impaired (2,3), but it remains controversial to what extent the defect is caused by a reduced release of incretin hormones and whether this reduction occurs prior to the development of type 2 diabetes.”
BackgroundAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Gender differences in insulin resistance, body composition, and energy balance
Geer, E. B., & Shen, W. (2009) · Gender Medicine · doi:10.1016/j.genm.2009.02.002 · Cited by 913
Seltzer, H. S., Allen, E. W., Herron, A. L., & Brennan, M. T. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105534 · Cited by 883 · cited 4×
“These findings are in agreement with the glucoregulatory effects of GLP-1 (33,34) and with studies showing that infusion of the GLP-1 receptor antagonist exendin-(9-39) reduced first-phase insulin release and decreased insulin action in healthy individuals and in patients with type 2 diabetes (35,36).”
BackgroundMethodResultInfluentialNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 1×
“The incretin hormones GLP-1 and glucose-dependent insulinotropic polypeptide contribute to glucose-stimulated insulin release and therefore play important roles in maintaining normal glucose regulation (1).”
BackgroundDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
Validation of the insulin sensitivity index (ISI0,120): comparison with other measures
Gutt, M., Davis, C. L., Spitzer, S. B., Llabre, M. M., Kumar, M., Czarnecki, E. M., Schneiderman, N., Skyler, J. S., & Marks, J. B. (2000) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00116-3 · Cited by 474
Cited by
Items 201–300 of 325
Afferent Endocrine Control of Eating
Langhans, W., & Holst, J. J. (2016) · Wiley eBooks · doi:10.1002/9781118839317.ch2 · Cited by 8
Self-citationRathish, D., Senavirathna, I., Jayasumana, C., Agampodi, S. B., & Siribaddana, S. (2018) · Environmental Science and Pollution Research · doi:10.1007/s11356-018-3818-9 · Cited by 8
Mirzaei, F., Khodadadi, I., Majdoub, N., Vafaei, S. A., Tayebinia, H., & Oshaghi, E. A. (2022) · The Open Medicinal Chemistry Journal · doi:10.2174/18741045-v16-e2212130 · Cited by 7
Hoffmann, C., Schwarz, P. E. H., Mantzoros, C. S., Birkenfeld, A. L., Wolfrum, C., Solimena, M., Bornstein, S. R., & Perakakis, N. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110636 · Cited by 8
Sex Differences in Glucose Homeostasis
Arioglu‐Inan, E., & Kayki‐Mutlu, G. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_664 · Cited by 9
Dorling, J. L., Church, T. S., Myers, C. A., Höchsmann, C., White, U. A., Hsia, D. S., Martin, C. K., & Apolzan, J. W. (2019) · Nutrients · doi:10.3390/nu11092018 · Cited by 7
Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease
Jørgensen, M. B., Idorn, T., Rydahl, C., Hansen, H. P., Bressendorff, I. O., Brandi, L., Albrechtsen, N. J. W., van Hall, G., Hartmann, B., Holst, J. J., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz048 · Cited by 8
Self-citationLarsson, M., Patrone, C., von Euler, M., Holst, J. J., & Nathanson, D. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0896-z · Cited by 7
Self-citationKour, S., & Singh, S. (2025) · Phytomedicine Plus · doi:10.1016/j.phyplu.2025.100825 · Cited by 9
Peptide YY and Glucagon-like Peptide-1 Secretion in Obesity
Wilbrink, J., van Avesaat, M. H. P., Stronkhorst, A., Troost, F. J., le Roux, C. W., & Masclee, A. (2024) · Gastrointestinal Disorders · doi:10.3390/gidisord7010003 · Cited by 6
“This observation has been confirmed by Færch et al. [18], who investigated a large group of individuals with obesity with normal and with impaired glucose tolerance and type 2 diabetes.”
Sjúrðarson, T., & Nordsborg, N. B. (2025) · The Journal of Physiology · doi:10.1113/jp288202 · Cited by 6
Hong, S., Jung, C. H., Han, S. Y., & Park, C. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0253 · Cited by 6
Hassanzadeh-Rostami, Z., Ghobadi, S., & Faghih, S. (2022) · Nutrition Reviews · doi:10.1093/nutrit/nuac056 · Cited by 6
Valle, A. L., d’Annunzio, G., Campanello, C., Tantari, G., Pistorio, A., Napoli, F., Patti, G., Crocco, M., Bassi, M., Minuto, N., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02030-6 · Cited by 6
Evans, L. L., Lee, W. G., Karimzada, M., Patel, V. H., Aribindi, V. K., Kwiat, D. A., Graham, J. L., Cummings, D. E., Havel, P. J., & Harrison, M. R. (2023) · Obesity Surgery · doi:10.1007/s11695-023-07012-4 · Cited by 6
Bannon, C. A. M., Meek, C. L., Reimann, F., & Gribble, F. M. (2024) · Peptides · doi:10.1016/j.peptides.2024.171186 · Cited by 7
“GLP-1 levels post oral glucose were inversely related to BMI, whereas fasting GLP-1 levels were not different between BMI groups in adult participants [17] or slightly reduced in obesity in other studies [18,19].”
Advances in incretin therapies for targeting cardiovascular disease in diabetes
Roberts, T. D., Hutchinson, D. S., Wootten, D. L., Blasio, M. J. D., & Ritchie, R. H. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.03.007 · Cited by 7
Vella, A. V., & Cobelli, C. (2015) · Diabetes · doi:10.2337/db15-0292 · Cited by 6
Jalleh, R. J., Marathe, C. S., Trahair, L. G., Jones, K. L., & Horowitz, M. (2023) · Nutrients · doi:10.3390/nu15183889 · Cited by 6
“In a prior study [23] in youths with obesity, neither GIP or GLP-1 responses differed significantly in biphasic or monophasic cohorts; however, the GLP-1 response to oral glucose is known to be reduced in individuals with obesity, which may account for this difference in observations [24].”
BackgroundCheng, W., Geng, S., Li, Y., Chen, R., & Du, Z. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae557 · Cited by 6
Bara, J. K., Gandhi, P., & Verma, P. K. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02398-8 · Cited by 8
“In a longitudinal cohort study, Faerch and group [ 9 ] compared GLP-1 response in prediabetic, T2DM patients and healthy controls.”
Effect of liraglutide on the dysglycemia, inflammation, and gut microbiota in prediabetic KKay mice
Zhang, Y., Yang, X., Yang, P., Sun, H., Chen, L., Zhang, X., & Liu, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1714859 · Cited by 6
Gut Peptide Alterations in Type 2 Diabetes and Obesity: A Narrative Review
Tzeravini, E., Simati, S., Anastasiou, I. A., Dalamaga, Μ., & Kokkinos, A. D. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00687-7 · Cited by 8
“The same study reported higher GLP-1 levels in older individuals, possibly due to impaired renal function and reduced GLP-1 clearance [83]. diabetes or prediabetes secondary to pancreatitis compared to those with pre-existing T2DM or prediabetes before the onset of pancreatitis [67].”
Huang, X., Li, S., Yang, M., Xu-quan, F., Li, H., Tong, Y., Liu, Y., Chen, L., Lan, L., Li, L., et al. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.01.033 · Cited by 6
Sakornyutthadej, N., Mahachoklertwattana, P., Chanprasertyothin, S., Pongratanakul, S., Khlairit, P., & Poomthavorn, P. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13303 · Cited by 6
Exposure–Response Analysis of Cardiovascular Outcome Trials With Incretin-Based Therapies
Pan, Q., Yuan, M., & Guo, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.893971 · Cited by 5
VISENTIN, R., Brodersen, K., Richelsen, B., Møller, N., Man, C. D., Pedersen, A. K., Abrahamsen, J., Holst, J. J., & Nielsen, M. F. (2023) · Journal of Diabetes Research · doi:10.1155/2023/7127426 · Cited by 6
Self-citationWikarek, T., Kocełak, P., Owczarek, A. J., Chudek, J. T., & Olszanecka‐Glinianowicz, M. (2020) · International Journal of Endocrinology · doi:10.1155/2020/4603682 · Cited by 6
Babenko, A. Y., Matveev, G. A., Алексеенко, Т. И., Derevitskii, I. V., Kokina, M. A., & Shlyakhto, E. V. (2020) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2019-25-6-639-652 · Cited by 6
Samad, A. R., Rajpoot, N. N., Ayaz, H., & Sadiq, N. (2019) · Journal of Bahria University Medical and Dental College · doi:10.51985/jbumdc2018125 · Cited by 5
Gerstenberg, M. K., Andersen, D. B., Torz, L., Castorena, C. M., Bookout, A. L., Hartmann, B., Rehfeld, J. F., Petersen, N., Holst, J. J., & Kuhre, R. E. (2023) · Acta Physiologica · doi:10.1111/apha.13947 · Cited by 5
Self-citationRuchko, E., Maria, C., Sokolov, V., Starinnov, Z. R., Sabirov, M. S., & Vasiliev, A. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1698296 · Cited by 4
The Natural History of Prediabetes and Cardiovascular Disease in the Pediatric Population
Accacha, S. D., Barillas, J., Gabriel, L., Srivastava, A., Gulkarov, S., Apsan, J., Leon, J. D., & Reiss, A. B. (2026) · Biomedicines · doi:10.3390/biomedicines14010198 · Cited by 4
“Following an oral glucose challenge, GLP-1 levels are reduced in individuals with impaired glucose tolerance and prediabetes [168].”
Engelbrechtsen, L., Iepsen, E. W., Galijatovic, E. A. A., Mahendran, Y., Lundgren, J. R., Jonsson, A. E., Madsbad, S., Holst, J. J., Vestergaard, H., Hansen, T. F., et al. (2016) · Metabolomics · doi:10.1007/s11306-016-1128-0 · Cited by 5
“Obese individuals have impaired endogenous GLP-1 secretion (Færch et al. 2015) and weight loss induces a marked increase in meal-induced GLP-1 responses (Iepsen et al.”
BackgroundSelf-citationLee, M. H., Febriana, E., Lim, M., Baig, S., Halter, J. B., Magkos, F., & Toh, S.-A. E. S. (2023) · Obesity · doi:10.1002/oby.23833 · Cited by 4
Shestakova, E. A., Stafeev, I., Yashkov, Y., Yurasov, A., Tomilova, A., Parfyonova, Y. V., Shestakova, M. V., & Dedov, I. I. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226998 · Cited by 4
Rafiei, H., & Little, J. P. (2025) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2024-0532 · Cited by 4
Su, Y., Zhang, S., Wu, Z., Liu, W.-T., Chen, J., Deng, F., Chen, F., Zhu, D., & Hou, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1054946 · Cited by 5
Krystyník, O., Karásek, D., Kahle, M., Kučerová, V., Mačáková, D., Cibičková, Ľ., Mráz, M., & Haluzík, M. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-00981-7 · Cited by 4
Peng, Z., Bao, L., Iben, J., Wang, S., Shi, B., & Shi, Y. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01257-x · Cited by 3
“EECs are often dysregulated in obesity and type 2 diabetes patients [11, 12].”
BackgroundSleep and Circadian Effects on the Incretin System
Yuan, R. K., & Zitting, K. (2025) · Current Sleep Medicine Reports · doi:10.1007/s40675-025-00337-9 · Cited by 3
Gübeli, A., Steiner, N., Limacher, A., Mathis, D., Melmer, A., & Laimer, M. W. (2025) · Diabetologia · doi:10.1007/s00125-025-06481-9 · Cited by 3
Javidi, D. J., Webb, D., Tartera, H. O. D., Ud‐din, M., Elias, K., Sundbom, M., & Hellström, P. M. (2025) · Neurogastroenterology & Motility · doi:10.1111/nmo.70163 · Cited by 3
“This is of importance for the release and effects of GLP-1, where we today have broad knowledge of its attenuated meal response in obesity [2].”
Lin, Y.-H., & Huang, H. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s220180 · Cited by 4
“The Danish ADDITION-PRO study reported that obese and overweight individuals had up to 20% reduction in plasma glucagon-like peptide-1 (pGLP-1) response to an oral glucose tolerance test compared with those with normal weight.(24) pGLP-1 is an insulinotropic incretin produced by enteroendocrine L cells in the small in…”
BackgroundMechanistic implications of diabetes leading to bone pathology
Konar, M., Kaur, B., & Sharma, S. (2024) · Journal of Orthopaedic Reports · doi:10.1016/j.jorep.2024.100485 · Cited by 5
Nugraha, I. B. A., Saraswati, M. R., & Suastika, K. (2019) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2019.030 · Cited by 3
Song, L., Wang, N., Zhang, J., Yu, L.-P., Chen, X., Zhang, B., & Yang, W. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i3.279 · Cited by 4
Ghrelin and glucagon-like peptide-1 according to body adiposity and glucose homeostasis
Lopes, K. G., da Silva, V. L., Lopes, F. D. A. M., Bouskela, E., de Souza, M. D. G. C., & Kraemer‐Aguiar, L. G. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000611 · Cited by 4
Barakat, G. M., Assi, G., Khalil, H., & Khatib, S. E. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998287178240403055901 · Cited by 3
Blaska, M., Gołąb-Jenerał, K., & Ziora, K. T. (2025) · Endokrynologia Polska · doi:10.5603/ep.104689 · Cited by 4
Effects of Weight-lowering Medications in People With Obesity and Rheumatic Diseases
Karacabeyli, D., & Lacaille, D. V. (2025) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-025-00232-y · Cited by 3
“Rises in GLP-1 (and GIP) following a glucose load are blunted in individuals with obesity, leading to less GLP-1 receptor activation [ 38 ].”
Targeting postprandial glycaemia in children with diabetes: O pportunities and challenges
Geyer, M. C., Rayner, C. K., Horowitz, M., & Couper, J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13141 · Cited by 5
Eriksen, R., White, M. C., Dawed, A. Y., García‐Pérez, I., Posma, J. M., Haid, M., Sharma, S., Prehn, C. P., Thomas, E. L., Koivula, R. W., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae119 · Cited by 3
“These data are supported by a few small studies reporting increases in fasting GLP-1 in T2D; however, our analysis of fasting GLP-1 is more extensive than any previous studies (5, 21-23).”
BackgroundResultInfluentialSelf-citationPonte, M. E., Prom, J. C., Newcomb, M. A., Jordan, A. B., Comfort, L. L., Hu, J., Puchalska, P., Koestler, D. C., Geisler, C. E., Hayes, M. R., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102167 · Cited by 2
Effects of incretin drugs on glycemic control and body weight
Levitskaya, A. N., Demidova, T. Y., & Геннадьевна, Л. К. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-3-07 · Cited by 2
Goulet, V., Léveillé, D., Li, J., & Fisette, A. (2026) · Discover Endocrinology and Metabolism · doi:10.1007/s44417-026-00014-7 · Cited by 3
Bæch‐Laursen, C., Ucin, J. V., Galsgaard, K. D., Llana, J., Kissow, H., Rehfeld, J. F., Holst, J. J., Pedersen, B. K., & Sanchís, P. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106152 · Cited by 3
Self-citationGlucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes
Panou, T., Gouveri, E., Popovic, D. S., Papazoglou, D., & Παπάνας, Ν. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01865-5 · Cited by 2
“Impaired glucagon-like peptide-1 (GLP-1) action has been shown in prediabetes [10, 11].”
Jardon, K. M. C., Umanets, A., Venema, K., Trouwborst, I., Gijbels, A., Hul, G. B. J., Siebelink, E., Afman, L. A., Goossens, G. H., & Blaak, E. E. (2026) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2026.101340 · Cited by 2
Obesity without diabetes: the role of hormonal regulation
Shestakova, E. A., Sklyanik, I. A., Сергеевна, П. А., Nikankina, L. V., Shestakova, M. V., & Dedov, I. I. (2020) · Terapevticheskii arkhiv · doi:10.26442/00403660.2020.10.000750 · Cited by 2
“Отсутствие статистически значимых различий в концентрации ГПП-1 в нашей работе представляется нам особенностью данной выборки, так как зависимость секреции этого гормона как от выраженности нарушений углеводного обмена, так и от степени ожирения продемонстрирована в крупных исследованиях [17].”
Enteroendocrine Systems That Sense Nutrients in the Gut and Control the Body
Hira, T. (2022) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.68.s5 · Cited by 2
Chemerin loss‐of‐function attenuates glucagon‐like peptide‐1 secretion in exercised obese mice
Zhang, Q., Jia, Y., Guo, Y., Yu, X., Wang, R., & Wang, X. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16126 · Cited by 4
Circulating GLP-1 Levels in Patients with Pheochromocytoma/Paraganglioma
Chen, N., Chen, Y., Lai, F., Chen, L., Zeng, R., Pei, L., Wu, L., Wang, C., Li, Y., Xiao, H., et al. (2022) · International Journal of Endocrinology · doi:10.1155/2022/4203018 · Cited by 3
Role of FFAR3 in ketone body regulated glucagon-like peptide 1 secretion
Persson, S. M. T., Casselbrant, A., Alarai, A., Elebring, E., Fändriks, L., & Wallenius, V. (2024) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2024.101749 · Cited by 1
“It has been shown that GLP-1 secretion is blunted in obesity and T2D, which has been suggested to contribute to the decreased insulin secretion and increased insulin resistance seen in these conditions [10].”
Gitonga, C. G., Githinji, C. G., Chege, B. M., Bukachi, F., & Waweru, P. (2025) · PLoS ONE · doi:10.1371/journal.pone.0337172 · Cited by 1
“…of impaired glucose tolerance on the other hand has been shown to be characterized by heightened peripheral insulin resistance, normal hepatic insulin sensitivity, progressive ß-cell dysfunction, reduced secretion of the insulin-tropic hormones, and deranged glucagon secretion [27,30–33].”
Ticho, A. L., MCRAE, A. N., Cifuentes, L., Fredrick, T. W., Añazco, D., Espinosa, M. A., Cordova, J. M. G., Romanos, M., Villamarin, J. L., Johnson, S., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.05.019 · Cited by 1
Liu, Y., Ni, Y., Xie, C., Fan, L., Jiang, Y., Sun, Q., Mao, B., Huang, C., Zhang, Z., Yang, Y., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06781-8 · Cited by 1
“Given that intestinal glucose consistently triggers GLP-1 secretion, OGTT is an adequate tool for examining postprandial GLP-1 response [46].”
Færch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A. E., Pedersen, O. B., Hansen, T. F., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db15-0743 · Cited by 1
Self-citationThe importance of prediabetes and therapeutic approach
Altuntaş, Y., & Öztürk, F. Y. (2015) · SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital · doi:10.5350/semb.20151126122000 · Cited by 5
Glucagon-Like Peptide 1 and Human Obesity
Anandhakrishnan, A., & Korbonits, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48559-3.00003-8 · Cited by 1
Sheriba, N., Nasr, M. S., Adel, C., & Anas, S. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.11.024 · Cited by 1
Glucagon-like peptide-1 agonist therapy in patients with diabetes mellitus and obesity
Babenko, A. Y., Kononova, Y. A., Martjanova, M. V., Симаненкова, А. В., Kokina, M. A., & Shlyakhto, E. V. (2020) · Clinical Medicine (Russian Journal) · doi:10.30629/0023-2149-2020-98-3-210-217 · Cited by 1
Zengul, A. G., Hoover, S. E., & Chandler-Laney, P. C. (2020) · Pediatric Obesity · doi:10.1111/ijpo.12757 · Cited by 1
“GLP-1 promotes satiety and stimulates insulin secretion to lower blood glucose,(14) and individuals with insulin resistance and GDM have suppressed GLP-1 secretion.(15,16) Further, patients with T2D have impaired response to GLP-1 and blunted insulin secretion.”
BackgroundRole of gut microbiota in the pathogenesis of type 2 diabetes mellitus (literature review)
Koval, S. M., & Snihurska, I. O. (2021) · Medicni perspektivi · doi:10.26641/2307-0404.2021.4.248064 · Cited by 2
Exendin-4 Exacerbates Burn-Induced Mortality in Mice by Switching to Th2 Response
Hao, J.-W., Chen, Q., Liu, H., & Zhang, Q. (2022) · Journal of Surgical Research · doi:10.1016/j.jss.2022.07.029 · Cited by 2
Pappa, E. T., Busygina, K., Harada, S., Hermann, H., Then, C., Lechner, A., Ferrari, U., & Seißler, J. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003706 · Cited by 1
de Souza, E. A., Mennitti, L. V., Santamarina, A. B., Minari, T. P., Jucá, A., Sertorio, M. N., & Pisani, L. P. (2024) · European Journal of Nutrition · doi:10.1007/s00394-024-03485-w · Cited by 2
“However, the decrease in GLP-1 level is before the development of type 2 diabetes and obesity [26].”
Huang, W., Xie, C. H., Jones, K. L., Horowitz, M., Rayner, C. K., & Wu, T. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111880 · Cited by 1
Incretin hormones as a target for therapy
Holst, J. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-08982-9_2
Self-citationUse of a Nebulizer to Deliver High Frequency High Flow with a Nasal Cannula
Goldstein, M. (2017) · Academic Journal of Pediatrics & Neonatology · doi:10.19080/ajpn.2017.02.555619
Gastrointestinal Hormones and the Control of Food Intake and Energy Metabolism
PAGE, L. C., Miller, M. D., D’Alessio, D. D., & Tong, J. (2017) · Contemporary Endocrinology · doi:10.1007/978-3-319-68192-4_3 · Cited by 1
Uebelhack, R., Bongartz, U., Tan, B.-K., & Seibt, S. (2018) · PharmaNutrition · doi:10.1016/j.phanu.2018.06.002
Humans – The Ultimate Model for the Study of Neuroendocrine Systems
Yang, L., Izzi‐Engbeaya, C. N., & Dhillo, W. S. (2018) · Wiley eBooks · doi:10.1002/9781119391128.ch17
Modern Understanding of the Gut Microbiotа in Patients with Diabetes Mellitus
Чугунова, Е. В., & Darenskaya, M. A. (2021) · Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук · doi:10.29413/abs.2020-5.6.6
Inter- and intra-individual variability of active glucagon-like peptide 1 among healthy adults
Sylvetsky, A. C., Bauman, V., Abdelhadi, J., Blau, J. E., Wilkins, K. J., & Rother, K. I. (2020) · Journal of Translational Science · doi:10.15761/jts.1000404
Functional Study on the GLP-1 Based Drug Liraglutide in High Fat Diet Fed Mice
Khroud, M. (2020) · TSpace (University of Toronto)
Role of fasting duration and weekday in incretin and glucose regulation
Clemmensen, K. K. B., Quist, J. S., Vistisen, D., Witte, D. R., Jonsson, A. E., Pedersen, O. B., Hansen, T. F., Holst, J. J., Lauritzen, T., Jørgensen, M. E., et al. (2021) · Endocrine Abstracts · doi:10.1530/endoabs.77.ja4
Self-citationDescifrando las funciones de la microbiota intestinal en la obesidad.
López‐Almela, I. (2021) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/174897
Research Progress on the Relationship between Cerebral Infarction and Intestinal Microbiome
杨, 潇. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.117447
Secretion and Impact of Gut Hormones in Obesity and Diabetes
Holst, J. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00264-9
Self-citationVeränderungen der Sekretion und biologischen Wirksamkeit von Inkretinhormonen bei Typ-2-Diabetes
Quast, D. R., & Nauck, M. A. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01146-w
Osinski, C. (2022) · theses.fr (ABES) · doi:10.70675/c7178188z34c1z444ez8557zc84f98b33280
Incretins in healthy and type 2 diabetic people
Goglia, U. (2024) · The Journal of AMD · doi:10.36171/jamd24.27.2.3
Deischinger, C., Harreiter, J., & Kautzky‐Willer, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-65952-2_6
DiPietro, L., Malin, S. K., Barbiero, M., Levers, K. S., Heinz, E. R., & Napolitano, M. A. (2025) · Translational Journal of the American College of Sports Medicine · doi:10.1249/tjx.0000000000000284
Wilbrink, J. (2025) · Research Publications (Maastricht University) · doi:10.26481/dis.20250620jw
Bur, H., Hukkanen, J., Savolainen, M. J., Koivukangas, V., & Karttunen, T. J. (2025) · Physiological Reports · doi:10.14814/phy2.70489
“More recent analyses have shown that obesity is associated with a decreased GLP-1 secretion regardless of glucose tolerance status, with GLP-1 responses showing an inverse association with obesity (Faerch et al., 2015; Holst, 2024).”
Jang, H. N., Hong, E. S., Yang, Y., Lee, S. O., Jang, M., Mari, A., Kwak, S. H., Park, K. S., Jang, H. C., & Jung, H. S. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0741
“Plasma GLP-1 levels have been suggested to be influenced by various factors such as plasma dipeptidyl peptidase-4 (DPP-4) levels, race, age, gender, BMI, metformin use, and diabetic status [31-36].”
Peng, Z., Bao, L., Iben, J., Wang, S., Shi, B., & Shi, Y.-B. (2024) · Figshare · doi:10.6084/m9.figshare.25971787
Peng, Z., Bao, L., Iben, J., Wang, S., Shi, B., & Shi, Y.-B. (2024) · Figshare · doi:10.6084/m9.figshare.25971647
Metadata
- Authors
- Færch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., Holst, J. J., & Jørgensen, M. E.
- Affiliations
- Steno Diabetes Center, Gentofte, Denmark
- University of Copenhagen (DK)
- Danish Diabetes Academy (DK)
- Section for General Practice, Department of Public Health, Aarhus, Denmark
- Corresponding author
- Færch, Kristine
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2015-02-12
- Volume
- 64
- Issue
- 7
- Pages
- 2513-2525
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2081594150
- Cited by
- 321
- References
- 54
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 30 · 2023: 28 · 2022: 27 · 2021: 34 · 2020: 28 · 2019: 41 · 2018: 26 · 2017: 20 · 2016: 22 · 2015: 11
- FWCI
- 22.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Novo Nordisk Foundation
- Danish Centre for Evaluation and Health Technology Assessment
- Diabetes Fund of the National Board of Health
- Danish Medical Research Council
- Aarhus University Research Foundation
- European Foundation for the Study of Diabetes/Pfizer for Research into Cardiovascular Disease Risk Reduction in Patients with Diabetes (74550801)
- National Health Services in the counties of Copenhagen, Aarhus, Ringkøbing, Ribe, and Southern Jutland in Denmark
- Danish Council for Strategic Research
- Danish Research Foundation for General Practice
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucagon-like peptide-1, glucose-stimulated insulin secretion, prediabetes, type 2 diabetes, obesity, sex differences, oral glucose tolerance test, insulin sensitivity, beta-cell function
- MeSH terms
- Age Factors, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glucose Tolerance Test, Humans, Insulin, Male, Middle Aged, Obesity, Prediabetic State, Sex Characteristics, Body Mass Index, Glucagon-Like Peptide 1, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.